These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17121619)

  • 1. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
    Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
    [No Abstract]   [Full Text] [Related]  

  • 4. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
    Desai AA; Marks DJ
    Expert Rev Clin Immunol; 2010 Sep; 6(5):695-9. PubMed ID: 20828275
    [No Abstract]   [Full Text] [Related]  

  • 7. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA; van Olffen GH; Hageman G
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection and anti-tumor necrosis factor-alpha therapy.
    Zandman-Goddard G
    Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
    [No Abstract]   [Full Text] [Related]  

  • 9. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 10. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
    Keane J; Gershon S; Wise RP; Mirabile-Levens E; Kasznica J; Schwieterman WD; Siegel JN; Braun MM
    N Engl J Med; 2001 Oct; 345(15):1098-104. PubMed ID: 11596589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.
    Mancini G; Erario L; Gianfreda R; Oliva A; Massetti AP; Mastroianni CM; Vullo V
    Clin Microbiol Infect; 2007 Oct; 13(10):1036-7. PubMed ID: 17711485
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
    Sorrentino D; Terrosu G; Vadalà S; Avellini C
    Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Infectious risks of immunomodulating therapies in rheumatology].
    Van Delden C
    Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
    Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and nature of infectious disease in patients treated with anti-TNF agents.
    Raychaudhuri SP; Nguyen CT; Raychaudhuri SK; Gershwin ME
    Autoimmun Rev; 2009 Dec; 9(2):67-81. PubMed ID: 19716440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist.
    Rijkeboer A; Voskuyl A; Van Agtmael M
    Scand J Infect Dis; 2007; 39(1):80-3. PubMed ID: 17366020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.